Abe J, Umetsu R, Uranishi H, Suzuki H, Nishibata Y, Kato Y, Ueda N, Sasaoka S, Hatahira H,
Motooka Y, Masuta M, Nakamura M. Analysis of polypharmacy effects in older patients using
Japanese Adverse Drug Event Report database. PLoS One. 2017 Dec 21.
Abeyaratne C, Lalic S, Bell JS, Ilomäki J. Spontaneously reported adverse drug events related totapentadol and oxycodone/naloxone in Australia. Ther Adv Drug Saf. 2018 Apr; 9(4):197-205.
Ali AK, Watson DE. Pharmacovigilance Assessment of Immune-Mediated Reactions Reported for
Checkpoint Inhibitor Cancer Immunotherapies. Pharmacotherapy. 2017 Sep 26.
Ampadu HH, Hoekman J, de Bruin ML, Pal SN, Olsson S, Sartori D, Leufkens HG, Dodoo AN.
Adverse Drug Reaction Reporting in Africa and a Comparison of Individual Case Safety Report
Characteristics Between Africa and the Rest of the World: Analyses of Spontaneous Reports in
VigiBase®. Drug Saf. 2016 Jan 11.
Ancuceanu R, Dinu M, Furtunescu F, Boda D. An inventory of medicinal products causing skin rash:
Clinicalandregulatory

lessons.

Exp

Ther

Med.

2019

Dec;18(6):5061-5071.

doi:

10.3892/etm.2019.7837. Epub 2019 Jul 31.
Anderson LS, Bell HG, Gilbert M, Davidson JE, Winter C, Barratt MJ, Win B, Painter JL, Menone C,
Sayegh J, Dasgupta N. Using Social Listening Data to Monitor Misuse and Nonmedical Use of
Bupropion: A Content Analysis. JMIR Public Health Surveill. 2017 Feb 1; 3(1):e6.
Ankrah DNA, Darko DM, Sabblah G, Mantel-Teeuwisse A, Leufkens, HMG. Reporting of adverse
events following immunizations in Ghana - Using disproportionality analysis reporting ratios. Hum
Vaccin Immunother. 2017 Nov 27:1-7.
Anquetil C, Salem JE, Lebrun-Vignes B, et al. Evolving spectrum of drug-induced uveitis at the eraof immune checkpoint inhibitors results from the WHO's pharmacovigilance database. J Autoimmun.
2020;111:102454. doi:10.1016/j.jaut.2020.102454
Arana JE, Harrington T, Cano M, Lewis P, Mba-Jonas A, Rongxia L, Stewart B, Markowitz LE,
Shimabukuro TT. Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine
in the Vaccine Adverse Event Reporting System (VAERS), 2009-2015. Vaccine. 2018 Feb 21.
Aziz Y, Rademacher WMH, Hielema A, Wishaw SBP, van Diermen DE, de Lange J, Vissink A, Rozema
FR. Oral adverse effects: drug-induced tongue disorders. Oral Dis. 2020 Oct 14. doi: 10.1111/odi.13680.
Epub ahead of print. PMID: 33052611.

Bahk CY, Goshgarian M, Donahue K, Freifeld CC, Menone CM, Pierce CE, Rodriguez H, Brownstein
JS, Furberg R, Dasgupta N. Increasing Patient Engagement in Pharmacovigilance Through Online
Community Outreach and Mobile Reporting Applications: An Analysis of Adverse Event Reportingfor the Essure Device in the US. Pharmaceut Med. 2015;29(6):331-340.
Basilua JM, Pochart P. Cotrimoxazole Prophylaxis Is Not Associated with a Higher occurrence ofAtazanavir Treatment Failure: analysis of Worldwide Pharmacovigilance Data. Infect Disord Drug
Targets. 2019 Dec 19. doi: 10.2174/1871526520666191220112416. [Epub ahead of print] PMID:
31858913
Bayer S, Clark C, Dang O, Aberdeen J, Brajovic S, Swank K, Hirschman L, Ball R. ADE Eval: An
Evaluation of Text Processing Systems for Adverse Event Extraction from Drug Labels for
Pharmacovigilance. Drug Saf. 2020 Oct 2. doi: 10.1007/s40264-020-00996-3. Epub ahead of print.
PMID: 33006728.
Berg R, Shebl A, Kimber MC, Abraham M, Schreiber GB. Hemolytic events associated withintravenous immune globulin therapy: a qualitative analysis of 263 cases reported to four
manufacturers between 2003 and 2012. Transfusion. 2015 Jul;55 Suppl 2:S36-46.
Biagi C, Conti V, Montanaro N, Melis M, Buccellato E, Donati M, Covezzoli A, Amato R, Pazzi L,
Venegoni M, Vaccheri A, Motola D.

Comparative safety profiles of intravitreal bevacizumab,

ranibizumab and pegaptanib: the analysis of the WHO database of adverse drug reactions. Eur J Clin
Pharmacol. 2014 Sep 20.
Blake KV, Zaccaria C, Domergue F, La Mache E, Saint-Raymond A, Hidalgo-Simon A. Comparison
Between Paediatric and Adult Suspected Adverse Drug Reactions Reported to the European
Medicines Agency: Implications for Pharmacovigilance. Paediatr Drugs. 2014 Jun 5.
Bonaldo G, Vaccheri A, Melis M, Motola D. Drug-induced disseminated intravascular coagulation: apharmacovigilance study on World Health Organization's database [published online ahead of print,
2020 May 22]. J Thromb Thrombolysis. 2020;10.1007/s11239-020-02147-y. doi:10.1007/s11239-02002147-y
Bondon-Guitton E, Combret S, Pérault-Pochat MC, Stève-Dumont M, Bagheri H, Huguet F, Despas
F, Pathak A, Montastruc JL. Cardiovascular risk profile of patients with peripheral arterial occlusive
disease during nilotinib therapy. Target Oncol. 2016 Feb 19.

Bossard JB, Ponté C, Dupouy J, Lapeyre-Mestre M, Jouanjus E. Disproportionality Analysis for theAssessment of Abuse and Dependence Potential of Pregabalin in the French Pharmacovigilance
Database.Clin Drug Investig. 2016 Jun 14.
Brajovic S, Blaser DA, Zisk M, Caligtan C, Okun S, Hall M, Pamer CA. Validating a Framework for
Coding Patient-Reported Health Information to the Medical Dictionary for Regulatory Activities
Terminology:An

Evaluative

Study.

JMIR

MedInform.

2018

Aug

21;6(3):e42.

doi:

10.2196/medinform.9878.
Calderón MA, Rodríguez Del Río P, Vidal C, Just J, Pfaar O, Linneberg A, Demoly P. An EAACI"European Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI)": themethodology. Clin Transl Allergy. 2014 Jul 21;4:22.
Calderón MA, Vidal C, Rodríguez Del Río P, Just J, Pfaar O, Tabar AI, Sánchez-Machín I, Bubel P,
Borja J, Eberle P, Reiber R, Bouvier M, Lepelliez A, Klimek L, Demoly P; EASSI Doctors’ Group.
European Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI): a Real-Life
Clinical Assessment. Allergy. 2016 Oct 8.
Card T, Ungaro R, Bhayat F, Blake A, Hantsbarger G, Travis S. Vedolizumab use is not associatedwith increased malignancy incidence: GEMINI LTS study results and post-marketing data. Aliment
Pharmacol Ther. 2020 Jan;51(1):149-157. doi: 10.1111/apt.15538. Epub 2019 Nov 20. PMID: 31747086
Castillon G, Salvo F, Moride Y. The Social Impact of Suspected Adverse Drug Reactions: An analysisof the Canada Vigilance Spontaneous Reporting Database. Drug Saf. 2018 Aug 19. doi:
10.1007/s40264-018-0713-8.
Chen C, Borrego ME, Roberts MH, Raisch DW.

Comparison of post-marketing surveillance

approaches regarding infections related to tumor necrosis factor inhibitors (TNFi's) used in treatmentofautoimmune

diseases.

Expert

Opin

Drug

Saf.

2019

Jun

20:1-12.

doi:

10.1080/14740338.2019.1630063.
Chengwen T, Baus C,

Wilson JP,

Frei CR. Rhabdomyolysis Associations with Antibiotics: A

Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS). Int J Med Sci. 2019
Oct 15. doi: 10.7150/ijms.38605.
Cho SB, Lee AL, Chang HW, Kim KA, Yoo WJ, Yeom JA, Rho MH, Kim SJ, Lim YJ, Han M.
Prospective Multicenter Study of the Safety of Gadoteridol in 6163 Patients. J Magn Reson Imaging.
2019 Oct 29. doi: 10.1002/jmri.26940.

Chrétien B, Dolladille C, Hamel-Sénécal L, Sassier M, Faillie JL, Miremont-Salamé G, LelongBoulouard V, Le Boisselier R, Fedrizzi S, Alexandre J, Humbert X8. Comparative study of
hypoglycaemia induced by opioids. Is it a class effect? Expert Opin Drug Saf. 2019 Jul 24:1-6. doi:
10.1080/14740338.2019.1646246.
Chung AE, Shoenbill K, Mitchell SA, Dueck AC, Schrag D, Bruner DW, Minasian LM, St Germain D,
O'Mara AM, Baumgartner P, Rogak LJ, Abernethy AP, Griffin AC, Basch EM. Patient free text
reporting of symptomatic adverse events in cancer clinical research using the National Cancer
Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse
Events(PRO-CTCAE).

J

Am

Med

InformAssoc.

2019

Apr

1;26(4):276-285.

doi:

10.1093/jamia/ocy169.
Cloitre A, Duval X, Tubiana S, Giraud P, Veyrac G, Nosbaum A, Gouraud A, Mahé J, Lesclous P.
Antibiotic prophylaxis for the prevention of infective endocarditis for dental procedures is not
associated with fatal adverse drug reactions in France. Med Oral Patol Oral Cir Bucal. 2019 Apr 23.
pii: 22818. doi: 10.4317/medoral.22818.
Conte C, Rousseau V, Vert C, et al. Adverse drug reactions of statins in children and adolescents: adescriptive analysis from VigiBase, the WHO global database of individual case safety reports[published online ahead of print, 2020 Feb 5]. Fundam Clin Pharmacol. 2020;10.1111/fcp.12542.
doi:10.1111/fcp.12542
Crescioli G, Lombardi N, Bettiol A, Menniti-Ippolito F, Da Cas R, Parrilli M, Del Lungo M, Gallo E,
Mugelli A, Maggini V, Firenzuoli F, Vannacci A. Adverse events following Cannabis for medical use
in Tuscany: an analysis of the Italian Phytovigilance database. Br J Clin Pharmacol. 2019 Oct 27. doi:
10.1111/bcp.14140.
Cutroneo PM, Giardina C, Ientile V, Potenza S, Sottosanti L, Ferrajolo C, Trombetta CJ, Trifirò G.
Overview of the Safety of Anti-VEGF Drugs: Analysis of the Italian Spontaneous Reporting System.
Drug Saf. 2017 Jun 5.
Dagenais S, Scranton R, Joyce AR, Vick CC. A comparison of approaches to identify possible casesof local anesthetic systemic toxicity in the FDA Adverse Event Reporting System (FAERS) database.
Expert Opin Drug Saf. 2018 May 10:1-8.
de Vries ST, Harrison J, Revelle P, Ptaszynska-Neophytou A, Radecka A, Ragunathan G, Tregunno P,
Denig P, Mol PGM. Use of a Patient-Friendly Terms List in the Adverse Drug Reaction Report Form:A Database Study. Drug Saf. 2019 Feb 6. doi: 10.1007/s40264-019-00800-x.
Dietrich J, Gattepaille LM, Grum BA, et al. Adverse Events in Twitter-Development of a Benchmark
Reference Dataset: Results from IMI WEB-RADR [published online ahead of print, 2020 Jan 29].
Drug Saf. 2020;10.1007/s40264-020-00912-9. doi:10.1007/s40264-020-00912-9
Du J, Cai Y, Chen Y, He Y, Tao C. Analysis of Individual Differences in Vaccine Pharmacovigilance
Using VAERS Data and MedDRA System Organ Classes: A Use Case Study With Trivalent Influenza
Vaccine. Biomed Inform Insights. 2017 Apr 11.
Dubrall D, Schmid M, Stingl JC, Sachs B. Angioedemas associated with renin-angiotensin system
blocking drugs: Comparative analysis of spontaneous adverse drug reaction reports. PLoS One. 2020
Mar 26;15(3):e0230632. doi: 10.1371/journal.pone.0230632. eCollection 2020. PubMed PMID:
32214375; PubMed Central PMCID: PMC7098604.
Durup D(1), Schaffalitzky de Muckadell P(1), Strom CC(1). Evaluation of the reported rates ofhypersensitivity reactions associated with iron dextran and ferric carboxymaltose based on global
data from VigiBase™ and IQVIA™ MIDAS® over a ten-year period from 2008 to 2017. Expert Rev
Hematol. 2020 Mar 4. doi: 10.1080/17474086.2020.1738215. [Epub ahead of print] DOI:
10.1080/17474086.2020.1738215
Ehlken B, Nathell L, Gohlke A, Bocuk D, Toussi M, Wohlfeil S. Evaluation of the Reported Rates of
Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron (III) Isomaltoside1000 in Europe Based on Data from EudraVigilance and VigiBase™ between 2014 and 2017. Drug
Saf. 2018 Dec 10. doi: 10.1007/s40264-018-0769-5.
Emery P, Furst DE, Kirchner P, Melega S, Lacey S, Lehane PB. Risk of Malignancies in Patients with
Rheumatoid Arthritis Treated with Rituximab: Analyses of Global Postmarketing Safety Data andLong-Term Clinical Trial Data. Rheumatol Ther. 2019 Nov 21. doi: 10.1007/s40744-019-00183-6.
Eriksson R, Aagaard L, Jensen LJ, Borisova L, Hørlück D, Brunak S, Hansen EH. Discrepancies inlisted adverse drug reactions in pharmaceutical product information supplied by the regulatory
authorities in Denmark and the USA. Pharmacol Res Perspect. 2014 Jun;2(3).
Fahmy AI, Mekkawy MA, Abou-Ali A. Evaluation of bleeding adverse events associated with oral
P2Y12 inhibitors use in the Food and Drug Administration adverse event reporting system. Int J Clin
Pharmacol Ther. 2019 Feb 10. doi: 10.5414/CP203365.

Faisant C, Armengol G, Bouillet L, Boccon-Gibod I, Villier C, Lévesque H, Cottin J, Massy N,
Benhamou Y. Angioedema Triggered by Medication Blocking the Renin/Angiotensin System:
Retrospective Study Using the French National Pharmacovigilance Database. J Clin Immunol. 2015
Dec 28.
Felicetti P, Trotta F, Bonetto C, Santuccio C, Pernus YB, Burgner D, Chandler R, Girolomoni G,
Hadden RD, Kochar S, Kukucu M, Monaco G, Ozen S, Pahud B, Phuong L, Bachtiar NS, Teeba A, Top
K, Varricchio F, Wise RP18, Zanoni G19, Živkovic S, Bonhoeffer J; Brighton Collaboration Vasculitis
Working Group. Spontaneous reports of vasculitis as an adverse event following immunization: A
descriptive analysis across three international databases. Vaccine. 2015 Sep 18. pii: S0264410X(15)01293-1.
Freifeld CC, Brownstein JS, Menone CM, Bao W, Filice R, Kass-Hout T, Dasgupta N. Digital Drug
Safety Surveillance: Monitoring Pharmaceutical Products in Twitter. Drug Saf. 2014 Apr 29.
Fukuda A, Tahara K, Hane Y, Matsui T, Sasaoka S, Hatahira H, Motooka Y, Hasegawa S, Naganuma
M, Abe J, Nakao S, Takeuchi H, Nakamura M. Comparison of the adverse event profiles of
conventional and liposomal formulations of doxorubicin using the FDA adverse event reporting
system. PLoS One. 2017 Sep 27;12(9).
Gahr M, Zeiss R, Lang D, Connemann BJ, Hiemke C, Schönfeldt-Lecuona C. Drug-induced liver
injury associated with antidepressive psychopharmacotherapy: An explorative assessment based on
quantitative signal detection using different MedDRA terms. J Clin Pharmacol. 2015 Oct 16.
García MG, Larrinaga-Torrontegui U, Eduardo Martinez E, Lertxundi U, Palacios-Zabalza I, Aguirre
C. Fractures Related to Tenofovir: A Case/Noncase Study in the European Pharmacovigilance
Database. Am J Ther. 2018 Jan 8.
Gattás VL, Braga PE, Koike ME, Lucchesi MB, Precioso AR. Safety profile of heterologous serum
produced by the Butantan Institute, in São Paulo-SP, Brazil, from 2012 to 2015. Epidemiol Serv Saude.
2017 Jul-Sep;26(3):639-647.
Giancane G, Swart JF, Castagnola E, Groll AH, Horneff G, Huppertz HI, Lovell DJ, Wolfs T, Herlin
T, Dolezalova P, Sanner H, Susic G, Sztajnbok F, Maritsi D, Constantin T, Vargova V, Sawhney S,
Rygg M, K Oliveira S, Cattalini M, Bovis F, Bagnasco F, Pistorio A, Martini A, Wulffraat N, Ruperto
N; Paediatric Rheumatology International Trials Organisation (PRINTO). Opportunistic infections in
immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety
Adjudication Committee. Arthritis Res Ther. 2020 Apr 7;22(1):71. doi: 10.1186/s13075-020-02167-2.

PubMed PMID: 32264969; PubMed Central PMCID: PMC7136994.
Goedecke T, Ord K, Newbould V, Brosch S, Arlett P. Medication Errors: New EU Good Practice Guide
on Risk Minimisation and Error Prevention. Drug Saf. 2016 Mar 3.
Gopal S, Hough D, Karcher K, Nuamah I, Palumbo J, Berlin JA, Baseman A, Xu Y, Kent J. Risk ofcardiovascular morbidity with risperidone or paliperidone treatment: analysis of 64 randomized,
double-blind trials. J Clin Psychopharmacol. 2013 Apr;33(2):157-61.
Hasegawa S, Hatahira H, Naganuma M, Shimauchi A, Sasaoka S, Motooka Y, Fukuda A, Abe J,
Nakao S, Kato Y, Ohmori T, Iguchi K, Nakamura M. Adverse Event Trends Associated with OTC
Analgesic and Antipyretic Drug: Data Mining of the Japanese Adverse Drug Event Report Database.
Yakugaku Zasshi. 2017;137(10):1301-1311.
Hasegawa S, Ikesue H, Nakao S, et al. Analysis of immune-related adverse events caused by immune
checkpoint inhibitors using the Japanese Adverse Drug Event Report database [published online
ahead

of

print,

2020

Sep

1].

Pharmacoepidemiol

Drug

Saf.

2020;10.1002/pds.5108.

doi:10.1002/pds.5108
Hatahira H, Hasegawa S, Sasaoka S, Kato Y, Abe J, Motooka Y, Fukuda A, Naganuma M, Nakao S,
Mukai R, Shimada K, Hirade K, Kato T, Nakamura M. Analysis of fall-related adverse events amongolder adults using the Japanese Adverse Drug Event Report (JADER) database. J Pharm Health Care
Sci. 2018 Dec 17;4:32. doi: 10.1186/s40780-018-0129-8. eCollection 2018.
Hauben M, Hung E, Wood J. Soitkar A, Reshef D.

The impact of database restriction on

pharmacovigilance signal detection of selected cancer therapies. Ther Adv Drug Saf. 2017 May; 8(5):145-156.
He Y, Sarntivijai S, Lin Y, Xiang Z, Guo A, Zhang S, Jagannathan D, Toldo L, Tao C, Smith,
B. OAE: The Ontology of Adverse Events. Journal of Biomedical Semantics 2014, 5:29.
He Y, Toldo L, Burns G, Tao C, Abernethy DR. A 2012 Workshop: Vaccine and drug ontology in the
study of mechanism and effect (VDOSME 2012). J Biomed Semantics. 2012 Dec 18;3(1):12.
Hoffman KB, Dimbil M, Kyle RF, Tatonetti NP, Erdman CB, Demakas A, Chen D, Overstreet BM. A
Drug Safety Rating System Based on Postmarketing Costs Associated with Adverse Events andPatient Outcomes. J Manag Care Spec Pharm. 2015 Dec;21(12):1134-43.

Holländer-Mieritz C, Johansen J, Johansen C, Vogelius IR, Kristensen CA, Pappot H. Comparing thepatients' subjective experiences of acute side effects during radiotherapy for head and neck cancer
with four different patient-reported outcomes questionnaires. Acta Oncol. 2019 Jan 30:1-7. doi:
10.1080/0284186X.2018.1563713.
Honvo G, Leclercq V, Geerinck A, Thomas T, Veronese N, Charles A, Rabenda V , Beaudart C, Cooper
C, Reginster JY, Bruyère O. Drugs Aging. Safety of Topical Non-steroidal Anti-Inflammatory Drugs
in Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis. 2019 Apr;36(Suppl 1):45-64.
doi: 10.1007/s40266-019-00661-0.
Honvo G, Reginster JY, Rabenda V, Geerinck A, Mkinsi O, Charles A, Rizzoli R, Cooper C, Avouac B,
Bruyère O. Safety of Symptomatic Slow-Acting Drugs for Osteoarthritis: Outcomes of a Systematic
Review and Meta-Analysis Drugs Aging. 2019 Apr;36(Suppl 1):65-99. doi: 10.1007/s40266-019-00662z.
Honvo G, Reginster JY, Rannou F, Rygaert X, Geerinck A, Rabenda V, McAlindon T, Charles A, Fuggle
N, Cooper C, Curtis E, Arden N, Avouac B, Bruyère O. Safety of Intra-articular Hyaluronic Acid
Injections in Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis. Drugs Aging. 2019
Apr;36(Suppl 1):101-127. doi: 10.1007/s40266-019-00657-w.
Huang J, Jia Y, Sun S, Meng L. Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data
mining of the public version of the FDA adverse event reporting system. BMC Pharmacol Toxicol.
2020 Sep 16;21(1):68. doi: 10.1186/s40360-020-00447-w. PMID: 32938499; PMCID:
Inácio P, Airaksinen M, Cavaco A. Language does not come "in boxes": Assessing discrepancies
between adverse drug reactions spontaneous reporting and MedDRA® codes in European Portuguese.
Res Social Adm Pharm. 2014 Dec 5. pii: S1551-7411(14)00397-0.
Jessurun N, van Puijenbroek E. Relationship Between Structural Alerts in NSAIDs and Idiosyncratic
Hepatotoxicity: An Analysis of Spontaneous Report Data from the WHO Database. Drug Saf. 2015
Mar 19.
Ji HH, Tang XW, Dong Z, Song L, Jia YT. Adverse Event Profiles of Anti-CTLA-4 and Anti-PD-1
Monoclonal Antibodies Alone or in Combination: Analysis of Spontaneous Reports Submitted to
FAERS. Clin Drug Investig. 2019 Jan 23. doi: 10.1007/s40261-018-0735-0.
Jia Y, Zhu C, Du J, Xiang Y, Chen Y, Wang W, Tao C. Investigating safety profiles of humanpapillomavirus vaccine across group differences using VAERS data and MedDRA. PeerJ. 2019 Aug

20; 7:e7490. doi: 10.7717/peerj.7490. eCollection 2019.
Kang S, Niak A, Gada N, Brinker A, Jones SC. Etonogestrel implant migration to the vasculature,chest wall, and distant body sites: cases from a pharmacovigilance database. Contraception. 2017 Sep
1.
Karapetiantz P, Bellet F, Audeh B, Lardon J, Leprovost D, Aboukhamis R, Morlane-Hondère F, Grouin
C, Burgun A, Katsahian S, Jaulent MC, Beyens MN, Lillo-Le Louët A, Bousquet C. Descriptions ofAdverse Drug Reactions Are Less Informative in Forums Than in the French Pharmacovigilance
Database but Provide More Unexpected Reactions. Front Pharmacol. 2018 May 1; 9:439. 2018.
Karimi S, Kemps M, Metke-Jimenez A, Wang C.2

Cadec: A Corpus of Adverse Drug Event

Annotations. J Biomed Inform. 2015 Mar 26. pii: S1532-0464(15)00053-2.
Lasky JA, Criner GJ, Lazarus HM, Kohlbrenner V, Bender S, Richeldi L. Safety of Nintedanib in
Patients with Idiopathic Pulmonary Fibrosis: Global Pharmacovigilance Data [published online
ahead of print, 2020 Aug 7]. Adv Ther. 2020;10.1007/s12325-020-01452-5. doi:10.1007/s12325-02001452-5
Laubach JP, Moslehi JJ, Francis SA, San Miguel JF, Sonneveld P, Orlowski RZ, Moreau P, Rosiñol L,
Faber EA Jr, Voorhees P, Mateos MV, Marquez L, Feng H, Desai A, van de Velde H, Elliott J, Shi H,
Dow E, Jobanputra N, Esseltine DL, Niculescu L, Anderson KC, Lonial S, Richardson PG. A
retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple
myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in
multiple myeloma. Br J Haematol. 2017 May 3.
Lavonas EJ, Banner W, Bradt P, Bucher-Bartelson B, Brown KR, Rajan P, Murrelle L, Dart RC, GreenJL. Root Causes, Clinical Effects, and Outcomes of Unintentional Exposures to Buprenorphine by
Young Children. J Pediatr. 2013 Nov;163(5):1377-83.
Ly T, Pamer C, Dang O, Brajovic S, Haider S, Botsis T, Milward D, Winter A, Lu S, Ball R. J.
Evaluation of Natural Language Processing (NLP) Systems to Annotate Drug Product Labeling with
MedDRA Terminology. Biomed Inform. 2018 May 31.
Mali G, Ahuja V, Dubey K. Glucagon-like peptide-1 analogues and thyroid cancer: An analysis of cases
reported in the European pharmacovigilance database. J Clin Pharm Ther. 2020 Sep 14. doi:
10.1111/jcpt.13259. Epub ahead of print. PMID: 32926446.

Marcilly R, Douze L, Ferré S, Audeh B, Bobed C, Lillo-Le Louët A, Lamy JB, Bousquet C. How tointeract with medical terminologies? Formative usability evaluations comparing three approaches forsupporting the use of MedDRA by pharmacovigilance specialists. BMC Med Inform Decis Mak. 2020
Oct 9;20(1):261. doi: 10.1186/s12911-020-01280-1. PMID: 33036603; PMCID: PMC7547416.
Martin Arias LH, Martin Gonzalez A, Sanz Fadrique R, Salgueiro E, Sainz M. Cardiovascular andgastrointestinal safety of selective cyclooxygenase-2 inhibitors: a case/non-case study. Int J Clin
Pharm. 2018 Jul 31. doi: 10.1007/s11096-018-0705-x.
Mendes D, Alves C, Loureiro M, Fonte A, Batel-Marques F. Drug-induced hypersensitivity: A 5-year
retrospective study in a hospital electronic health records database. J Clin Pharm Ther. 2018 Aug 1.
doi: 10.1111/jcpt.12752.
Mendes D, Oliveira AR, Alves C, Batel Marques F. Spontaneous reports of hypersensitivity adverse
drug reactions in Portugal: a retrospective analysis. Expert Opin Drug Saf. 2020 Mar 25:1-7. doi:
10.1080/14740338.2020.1743262. [Epub ahead of print] PubMed PMID: 32167395.
Merchant L, Lutter R, Chang S. Identical or similar brand names used in different countries for
medications with different active ingredients: a descriptive analysis [published online ahead of print,
2020 Apr 27]. BMJ Qual Saf. 2020;bmjqs-2019-010316. doi:10.1136/bmjqs-2019-010316
Min KC, Woo T, Assaid C, McCrea J, Gurner DM, Sisk CM, Adkinson F, Herring WJ. Incidence ofhypersensitivity and anaphylaxis with sugammadex. J Clin Anesth. 2018 Apr 2; 47:67-73.
Minjon L, van den Ban E, de Jong E, Souverein PC, Egberts TCG, Heerdink ER. Reported Adverse
Drug Reactions in Children and Adolescents Treated with Antipsychotics. J Child Adolesc
Psychopharmacol. 2019 Jan 24. doi: 10.1089/cap.2018.0139.
Miravitlles M, Price D, Rabe KF, Schmidt H, Metzdorf N, Celli B.Comorbidities of patients intiotropium clinical trials: comparison with observational studies of patients with chronic obstructive
pulmonary disease.Int J Chron Obstruct Pulmon Dis. 2015 Mar 16;10:549-64. 2015.
Misu T, Kortepeter CM, Muñoz MA, Wu E, Dal Pan GJ. An Evaluation of "Drug Ineffective"
Postmarketing Reports in Drug Safety Surveillance. Drugs Real World Outcomes. 2018 Feb 23.
Moja L, Lucenteforte E, Kwag KH, Bertele V, Campomori A, Chakravarthy U, D'Amico R, Dickersin
K, Kodjikian L, Lindsley K, Loke Y, Maguire M, Martin DF, Mugelli A, Mühlbauer B, Püntmann I,
Reeves B, Rogers C, Schmucker C, Subramanian ML, Virgili G. Systemic safety of bevacizumabversus ranibizumab for neovascular age-related macular degeneration. Cochrane Database Syst Rev.
2014 Sep 15;9:CD011230.
Monaco L, Melis M, Biagi C, Donati M, Sapigni E, Vaccheri A, Motola D. Signal detection activity on
EudraVigilance data: analysis of the procedure and findings from an Italian Regional Centre for
Pharmacovigilance. Expert Opin Drug Saf. 2017 Jan 30:1-5.
Moore TJ, Glenmullen J, Mattison DR. Reports of Pathological Gambling, Hypersexuality, andCompulsive Shopping Associated With Dopamine Receptor Agonist Drugs. JAMA Intern Med. 2014
Oct 20.
Moro PL, Winiecki S, Lewis P, Shimabukuro TT, Cano M. Surveillance of adverse events after the
first trivalent inactivated influenza vaccine produced in mammalian cell culture (Flucelvax®)
reported to the Vaccine Adverse Event Reporting System (VAERS), United States, 2013-2015. Vaccine.
2015 Oct 27. pii: S0264-410X(15)01527-3.
Moro PL, Woo EJ, Paul W, Lewis P, Petersen BW, Cano M . Post-Marketing Surveillance of Human
Rabies Diploid Cell Vaccine (Imovax) in the Vaccine Adverse Event Reporting System (VAERS) in the
United States. PLoS Negl Trop Dis. 2016 Jul 13;10(7):e0004846.
Motola D, Donati M, Biagi C, Calamelli E, Cipriani F, Melis M, Monaco L, Vaccheri A, Ricci G. Safety
profile of H1-antihistamines in pediatrics: an analysis based on data from VigiBase.
Pharmacoepidemiol Drug Saf. 2017 Jun 27.
Mukai J, Maruyama S, Otori K, Kubota R. [Antidepressant Medication Use and Development ofHyperglycemia and Diabetes Mellitus: A Japanese Adverse Drug Event Report Database Study].
Yakugaku Zasshi. 2020;140(4):591-598. doi: 10.1248/yakushi.19-00196. Japanese. PubMed PMID:
32238642.
Mukai M, Mould D, Maeda H, Narushima K, Greene D. Exposure-Response Analysis for
Mogamulizumab in Adults With Cutaneous T-Cell Lymphoma. J Clin Pharmacol. 2020 Jan;60(1):5057. doi: 10.1002/jcph.1548. Epub 2019 Dec 16. PMID: 31840837
Naganuma M, Tahara K, Hasegawa S, Fukuda A, Sasaoka S, Hatahira H, Motooka Y, Nakao S, Mukai
R, Hirade K, Yoshimura T, Kato T, Takeuchi H, Nakamura M. Adverse event profiles of solvent-based
and nanoparticle albumin-bound paclitaxel formulations using the Food and Drug Administration
Adverse Event Reporting System.
10.1177/2050312119836011.

SAGE Open Med. 2019 Mar 11;7:2050312119836011. doi:Nakao S, Hasegawa S, Shimada K, et al. Evaluation of anti-infective-related Clostridium difficileassociated colitis using the Japanese Adverse Drug Event Report database. Int J Med Sci.
2020;17(7):921‐930. Published 2020 Mar 26. doi:10.7150/ijms.43789
Narushima D, Kawasaki Y, Takamatsu S, Yamada H. Adverse events associated with incretin-based
drugs in Japanese spontaneous reports: a mixed effects logistic regression model. PeerJ. 2016 Mar 8.
Nasso C, Mecchio A, Rottura M, et al. A 7-Years Active Pharmacovigilance Study of Adverse Drug
Reactions Causing Children Admission to a Pediatric Emergency Department in Sicily. Front
Pharmacol. 2020;11:1090. Published 2020 Jul 17. doi:10.3389/fphar.2020.01090
Neeland IJ, Eliasson B, Kasai T, Marx N, Zinman B, Inzucchi SE, Wanner C, Zwiener I, Wojeck BS,
Yaggi HK, Johansen OE; EMPA-REG OUTCOME Investigators. The Impact of Empagliflozin on
Obstructive Sleep Apnea, Cardiovascular, and Renal Outcomes: An Exploratory Analysis of the
EMPA-REG OUTCOME Trial. Diabetes Care. 2020 Oct 1:dc201096. doi: 10.2337/dc20-1096. Epubahead of print. PMID: 33004464.
Nevin RL, Byrd AM. Neuropsychiatric Adverse Reactions to Mefloquine: a Systematic Comparison of
Prescribing and Patient Safety Guidance in the US, UK, Ireland, Australia, New Zealand, andCanada. Neurol Ther.2016 May 30.
Newbould V, Le Meur S, Goedecke T, Kurz X. Medication Errors: A Characterisation of Spontaneously
Reported Cases in EudraVigilance. Drug Saf. 2017 Jul 11.
Nishtala PS, Gill S, Chyou TY. Analysis of the US FDA adverse event reporting system to identify
adverse cardiac events associated with hydroxychloroquine in older adults. Pharmacoepidemiol Drug
Saf. 2020 Oct 19. doi: 10.1002/pds.5155. Epub ahead of print. PMID: 33078448.
Novitt-Moreno A, Ransom J, Dow G, Smith B, Read LT, Toovey S, Tafenoquine for malaria prophylaxis
in adults: An integrated safety analysis. Travel Med Infect Dis. 2017 May 8.
Ogar CK, Abiola A, Yuah D, et al. A Retrospective Review of Serious Adverse Drug Reaction Reports
in the Nigerian VigiFlow Database from September 2004 to December 2016. Pharmaceut Med.
2019;33(2):145–157. doi:10.1007/s40290-019-00267-2
Ohyama K, Inoue M. Association between Selective Beta-adrenergic Drugs and Blood Pressure
Elevation: Data Mining of the Japanese Adverse Drug Event Report (JADER) Database. Yakugaku

Zasshi. 2016; 136(7):1065-71.
Orion K, Mack J, Kullak-Ublick GA, Weiler S. Kounis syndrome: A retrospective analysis of individual
case safety reports from the international WHO database in pharmacovigilance. Int J Clin Pharmacol
Ther. 2019 Mar 22. doi: 10.5414/CP203344.
Patel R, Belousov M, Jani M, Dasgupta N, Winokur C, Nenadic G, Dixon WG. Frequent discussion of
insomnia and weight gain with glucocorticoid therapy: An analysis of Twitter posts. NPJ Digit Med.
2018 Feb 12;1. doi: 10.1038/s41746-017-0007-z.
Perino J, Mottal N, Bohbot Y, Servant V, Berroneau A, Poustis P, Fenaux P, Laribi K, Charbonnier A,
Bilion E, Calmettes C, Bégaud B, Pigneux A, Milpied N, Miremont-Salamé G, Théophile H, DimicoliSalazar S. Cardiac failure in patients treated with azacitidine, a pyrimidine analogue: case reports
and disproportionality analyses in Vigibase®. Br J Clin Pharmacol. 2020 Jan 7. doi: 10.1111/bcp.14211.
[Epub ahead of print]

PMID: 31912911
Pierce CE, Bouri K, Pamer C, Proestel S, Rodriguez HW, Van Le H, Freifeld CC, Brownstein JS,
Walderhaug M, Edwards IR, Dasgupta N . Evaluation of Facebook and Twitter Monitoring to Detect
Safety Signals for Medical Products: An Analysis of Recent FDA Safety Alerts. Drug Saf. 2017 Jan 2.
Pinheiro L, Blake K, Januskiene J, Yue QY, Arlett P. Geographical variation in reporting Interstitial
Lung Disease as an adverse drug reaction: findings from an European Medicines Agency analysis ofreports in EudraVigilance. Pharmacoepidemiol Drug Saf. 2016 Mar 22.
Pollock RF, Biggar P. Indirect methods of comparison of the safety of ferric derisomaltose, iron sucroseand ferric carboxymaltose in the treatment of iron deficiency anemia. Expert Rev Hematol.
2020;13(2):187–195. doi:10.1080/17474086.2020.1709437
Powell GE, Seifert HA, Reblin T, Burstein PJ, Blowers J, Menius JA, Painter JL, Thomas M, Pierce
CE, Rodriguez HW, Brownstein JS, Freifeld CC, Bell HG, Dasgupta N. Social Media Listening for
Routine Post-Marketing Safety Surveillance. Drug Saf. 2016 Jan 21.
Pratley RE, Husain M, Lingvay I, Pieber TR, Mark T, Saevereid HA, Møller DV, Zinman B; DEVOTE
Study Group. Heart failure with insulin degludec versus glargine U100 in patients with type 2
diabetes at high risk of cardiovascular disease: DEVOTE 14. Cardiovasc Diabetol. 2019 Nov
15;18(1):156. doi: 10.1186/s12933-019-0960-8.

Rademacher WMH, Aziz Y, Hielema A, Cheung KC, de Lange J, Vissink A, Rozema FR. Oral adverse
effects of drugs: taste disorders. Oral Dis. 2019 Sep 18. doi: 10.1111/odi.13199.
Raschi E, Poluzzi E1, Koci A, Antonazzo IC, Marchesini G, De Ponti F. Dipeptidyl peptidase-4
inhibitors and heart failure: Analysis of spontaneous reports submitted to the FDA Adverse Event
Reporting System. Nutr Metab Cardiovasc Dis. 2016 Feb 19. pii: S0939-4753(15)30192-7.
Reiber R, Wolf H, Schnitker J, Wüstenberg E. Tolerability of an Immunologically Enhanced
Subcutaneous Immunotherapy Preparation in Patients Treated with Concomitant Allergy
Immunotherapy: A Non-Interventional Observational Study. Drugs Real World Outcomes. 2017 Jan
9.
Rochoy M, Auffret M, Béné J, Gautier S; Réseau français des centres régionaux de pharmacovigilance.
Antiemetics and cardiac effects potentially linked to prolongation of the QT interval: Case/non-caseanalysis in the national pharmacovigilance database Rev Epidemiol Sante Publique. 2016 Dec 14. pii:
S0398-7620(16)30811-2.
Rodríguez Del Río P, Vidal C, Just J, Tabar AI, Sanchez-Machin I, Eberle P, Borja J, Bubel P, Pfaar
O, Demoly P, Calderón MA. The European Survey on Adverse Systemic Reactions in Allergen
Immunotherapy (EASSI): a paediatric assessment. Pediatr Allergy Immunol. 2016 Sep 17.
Sakai T, Ohtsu F, Sekiya Y, Mori C, Sakata H, Goto N. Methodology for Estimating the Risk of Adverse
Drug Reactions in Pregnant Women: Analysis of the Japanese Adverse Drug Event Report Database.
Yakugaku Zasshi. 2016;136(3):499-505.
Sandhu A, Kao D, Mehler PS, Haigney MC, Krantz MJ. Cardiovascular disorders associated withnaloxone monotherapy and in fixed-dose combination with opioids: Data from international safetysurveillance. Int J Cardiol. 2016 Jun 1;212:360-3.
Sarntivijai S, Xiang Z, Shedden KA, Markel H, Omenn GS, Athey BD, He Y. Ontology-based
combinatorial comparative analysis of adverse events associated with killed and live influenza
vaccines. PLoS One. 2012;7(11). Epub 2012 Nov 28.
Sasaoka S, Hatahira H, Hasegawa S1, Motooka Y, Fukuda A, Naganuma M, Umetsu R1, Nakao S,
Shimauchi A, Ueda N, Hirade K, Iguchi K, Nakamura M. Adverse Event Trends Associated with
Over-the-counter Combination Cold Remedy: Data Mining of the Japanese Adverse Drug Event
Report Database. Yakugaku Zasshi. 2018; 138(1):123 -134.

Schmitz B, Dimova S, Zhang Y, Chellun D, De Backer M, Gasalla T. Tolerability and efficacy oflacosamide and controlled-release carbamazepine monotherapy in patients with newly diagnosed
epilepsy and concomitant psychiatric conditions: Post hoc analysis of a prospective, randomized,
double-blind trial. Epilepsy Res. 2019 Oct 16;159:106220. doi: 10.1016/j.eplepsyres.2019.106220.
Schmitz SM MD, MPH1, Lopez HL MD, MS1,2, Mackay D ND3, Nguyen H BS3, Miller PE BS1.
Serious Adverse Events Reported with Dietary Supplement Use in the United States: A 2.5 Year
Experience. J Diet Suppl. 2018 Dec 4:1-22. doi: 10.1080/19390211.2018.1513109.
Sessa M, Mascolo A, Callréus T, Capuano A, Rossi F, Andersen M. Direct-acting oral anticoagulants(DOACs) in pregnancy: new insight from VigiBase®. Sci Rep. 2019 May 10;9(1):7236. doi:
10.1038/s41598-019-43715-4.
Sloan VS, Jones A, Maduka C, Bentz JWG. A Benefit Risk Review of Pediatric Use of
Hydrocodone/Chlorpheniramine, a Prescription Opioid Antitussive Agent for the Treatment of Cough.
Drugs Real World Outcomes. 2019 Jun;6(2):47-57. doi: 10.1007/s40801-019-0152-6.
Shimada K, Hasegawa S, Nakao S, Mukai R, Matsumoto K, Tanaka M, Uranishi H1,, Masuta M,
Nishida S, Shimizu S, Hayashi Y, Suzuki A, Nakamura M. Adverse event profiles of ifosfamideinduced encephalopathy analyzed using the Food and Drug Administration Adverse Event Reporting
System and the Japanese Adverse Drug Event Report databases. Cancer Chemother Pharmacol.
2019 Sep 9. doi: 10.1007/s00280-019-03949-5.
Stainsby CM, Perger TM, Vannappagari V, Mounzer KC, Hsu RK, Henegar CE, Oyee J, Urbaityte R,
Lane CE1, Carter LM, Pakes GE, Shaefer MS. Abacavir Hypersensitivity Reaction Reporting Rates
During a Decade of HLA-B*5701 Screening as a Risk Mitigation Measure. Pharmacotherapy. 2018
Nov 10. doi: 10.1002/phar.2196.
Tao C, He Y, Arabandi S. Vaccine and Drug Ontology Studies (VDOS 2014). J Biomed Semantics. 2016
Feb 25;7:6.
Tao C, Du J, Cai Y, Chen Y. Trivalent Influenza Vaccine Adverse Event Analysis Based On MedDRA
System Organ Classes Using VAERS Data. Stud Health Technol Inform. 2015;216:1076.
Tao C, He Y, Arabandi S. A 2013 workshop: vaccine and drug ontology studies (VDOS 2013). J Biomed
Semantics. 2014 Mar 20; 5(1):16.

Taylor E, Vu D, Legare C, Keene D. Intravenous immune globulin-related hemolysis: comparing two
different methods for case assessment. Transfusion. 2015 Jul;55 Suppl 2:S23-7.
Teng C, Reveles KR, Obodozie-Ofoegbu OO, Frei CR. Clostridium difficile Infection Risk with
Important Antibiotic Classes: An Analysis of the FDA Adverse Event Reporting System. Int J Med
Sci. 2019 May 7;16(5):630-635. doi: 10.7150/ijms.30739. eCollection 2019.
Teng C, Walter EA, Gaspar DKS, Obodozie-Ofoegbu OO, Frei CR.

Torsades de pointes and QT

prolongation Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event
Reporting System. Int J Med Sci. 2019 Jun 10;16(7):1018-1022. doi: 10.7150/ijms.34141.
Tourillon C, Mahe J, Baron A, Lambert A, Yélehé-Okouma M, Veyrac G, Jolliet P. Immediate-Type
Hypersensitivity Cross-Reactions to Proton Pump Inhibitors: A Descriptive Study of Data from the
French National Pharmacovigilance Database. Int Arch Allergy Immunol. 2018 Nov 28:1-8. doi:
10.1159/000493581.
Trippe ZA, Brendani B, Meier C, Lewis D. Identification of Substandard Medicines via
Disproportionality Analysis of Individual Case Safety Reports. Drug Saf. 2017 Jan 28.
Uemura N, Kinoshita Y, Haruma K, Yao T, Kushima R, Kanoo T. Rationale and design of the VISION
study: a randomized, open-label study to evaluate the long-term safety of vonoprazan as maintenancetreatment in patients with erosive esophagitis. Clin Exp Gastroenterol. 2018 Jan 24; 11:51-56.
Vacher R, Lagarce L, Ghamrawi S, Laugier-Castellan D, Vial T, Bagheri H, Babin M, Briet M. Druginteractions related to self-medication: a French pharmacovigilance database study. Fundam Clin
Pharmacol. 2020 Feb 16. doi: 10.1111/fcp.12546. [Epub ahead of print] PubMed PMID: 32064672.
van Hunsel F, van de Koppel S, van Puijenbroek E, Kant A. Vitamin B6 in Health Supplements and
Neuropathy: Case Series Assessment of Spontaneously Reported Cases. Drug Saf. 2018 May 8.
van Hunsel F, van de Koppel S, Skalli S, Kuemmerle A, Teng L, Wang JB, Barnes J. Analysis of
Hepatobiliary Disorder Reports Associated With the Use of Herbal Medicines in the Global Suspected
ADR Database Vigibase. Front Pharmacol. 2019 Nov 6;10:1326. doi: 10.3389/fphar.2019.01326.
eCollection 2019.
Vandael E, Vandenberk B, Vandenberghe J, Willems R, Foulon V. Cases of drug-induced Torsade dePointes: a review of Belgian cases in the EudraVigilance database. Acta Clin Belg. 2017 Mar 24: 1-6.

Vergani HM, Calvini G, Mangini G, Mattioli F, Parodi A, Burlando M, Bodini G, Martelli A. Active
pharmacovigilance program in patients affected by psoriasis and inflammatory bowel diseases. Int J
Clin Pharmacol Ther. 2020 Feb 12. doi:10.5414/CP203628. [Epub ahead of print] PubMed PMID:
32053103.
Vidal C, Rodríguez Del Río P, Gude F, Casale T, Cox L, Just J, Pfaar O, Demoly P, Calderón MA.
Comparison of International Systemic Adverse Reactions due to Allergen Immunotherapy. J Allergy
Clin Immunol Pract. 2018 Dec 14. pii: S2213-2198(18)30826-2. doi: 10.1016/j.jaip.2018.12.006.
Viola E, Opri S, Moretti U, Leone R, Casini ML, Ruggieri S, Minore C, Conforti A.α1-Adrenergic
receptor antagonists and gynecomastia. A case series from the Italian spontaneous reporting system
and VigiBase™Eur J Clin Pharmacol. 2014 Jun 3.
Vollmer O, Felten R, Mertz P, Lebrun-Vignes B, Salem JE, Arnaud L. Characterization of autoimmune hepatitis associated with the use of anti-TNFα agents: An analysis of 389 cases in VigiBase[published

onlineaheadofprint,

2020

Jan

7].

Autoimmun

Rev.

2020;102460.

doi:10.1016/j.autrev.2020.102460
Wang L, Li M, Cao Y, Han Z, Wang X, Atkinson EJ, Liu H, Amin. Proton Pump Inhibitors and the
Risk for Fracture at Specific Sites: Data Mining of the FDA Adverse Event Reporting System. Sci Rep.
2017 Jul 17.
Wise RA, Anderson JA, Amarenco P, et al. Adjudication of cardiovascular events in patients withchronic obstructive pulmonary disease: SUMMIT trial [published online ahead of print, 2020 May 22].
Clin Trials. 2020;1740774520920897. doi:10.1177/1740774520920897
Xie J, He Y. Ontology-Based Vaccine Adverse Event Representation and Analysis. Adv Exp Med Biol.
2017;1028:89-103.
Xie J, Zhao L, Zhou S, He Y. Statistical and Ontological Analysis of Adverse Events Associated with
Monovalent and Combination Vaccines against Hepatitis A and B Diseases. Sci Rep. 2016 Oct
3;6:34318.
Ye JH, Ho YF, On AW, Chen WW, Huang YM, Huang WI, Tang YW. Trends in reporting drugassociated liver injuries in Taiwan: a focus on amiodarone. Int J Clin Pharm. 2018 Jul 26. doi:
10.1007/s11096-018-0698-5.
Yu Y, Ruddy KJ, Hong N, Tsuji S, Wen A, Shah ND, Jiang G. ADEpedia-on-OHDSI: A Next Generation

Pharmacovigilance Signal Detection Platform Using the OHDSI Common Data Model. J Biomed
Inform. 2019 Feb 7:103119. doi: 10.1016/j.jbi.2019.103119.
Yue Z, Jiang P, Sun H, Wu J. Association between an excess risk of acute kidney injury andconcomitant use of ibuprofen and acetaminophen in children, retrospective analysis of a spontaneous
reporting system. Eur J Clin Pharmacol. 2014 Jan 21.
Zhang X, Zhong Z, Li Y, Li W. Long-term renal outcomes associated with sodium glucose
cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: A systematic review and metaanalysis. Diabetes Metab Res Rev. 2020 Mar 5:e3303. doi: 10.1002/dmrr.3303. [Epub ahead of print]
PubMed PMID: 32134558.
Zhu Z, Gao P, Hu Y, Wang J, Wang H, Yang J, Huang L, Ji C, Ni Y, Fang L. PEGylated versus nonPEGylated drugs: A cross-sectional analysis of adverse events in the FDA Adverse Event Reporting
System (FAERS) Database . Int J Clin Pharmacol Ther. 2020 Apr 23. doi: 10.5414/CP203735. [Epubahead of print] PubMed PMID: 32324132.
Ziemssen Fs, Hammer T, Grueb M, Mueller B, Berk H, Gamulescu MA, Voegeler J, Wachtlin J, Ocean
Study Group. Reporting of Safety Events during Anti-VEGF Treatment: Pharmacovigilance in a
Noninterventional Trial. J Ophthalmol. 2020 Oct 6;2020:8652370. doi: 10.1155/2020/8652370. PMID:
33083052; PMCID: PMC7558801.
Peng L, Xiao K, Ottaviani S, Stebbing J, Wang YJ. A real-world disproportionality analysis of FDA
Adverse Event Reporting System (FAERS) events for baricitinib. Expert Opin Drug Saf. 2020
Nov;19(11):1505-1511. doi: 10.1080/14740338.2020.1799975. Epub 2020 Jul 31.